FDA And Meningitis B: Picking Winners And Losers
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
PFE
Is Idera’s Sell-Off Premature?
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts
[Business Wire] – Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. The purpos moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here […]
1:40 am Pfizer provides detailed results of OPT Compare Phase 3 study of Tofacitinib 5 mg and 10 mg twice daily compared to high-dose ENBREL in adults with moderate-to-severe chronic plaque psoriasis
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
Tivicay® Tablets 50mg, HIV Integrase Inhibitor obtains approval in Japan
[at noodls] – PRESS RELEASE March 24, 2014 Tivicay® Tablets 50mg, HIV Integrase Inhibitor obtains approval in Japan New Treatment Option for Treatment-naïve Patients and Patients -Requiring an Alternative to Current … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
A Dividend Investing History Lesson – Pfizer And FirstEnergy Corporation
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
[Business Wire] – Pfizer Inc. announced today detailed results from OPT Compare , a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase inhibitors, the safety and efficacy of which are being investigated for the treatme moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee […]
Better Buy: Pfizer vs. CONSOL Energy
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
Investors Don’t Celebrate Celebrex Decision Favoring Cheap Generics
moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
[$$] Pressures Over Sale to Russian Firm
[at The Wall Street Journal] – China’s economy is failing to gain traction, but it’s too soon to hit the panic button. moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]
